SNSE Valuation
Sensei Biotherapeutics Inc
$
8.610
SNSE Relative Valuation
SNSE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNSE is overvalued; if below, it's undervalued.
Historical Valuation
Sensei Biotherapeutics Inc (SNSE) is now in the Fair zone, suggesting that its current forward PS ratio of 9.17 is considered Fairly compared with the five-year average of -2.64. The fair price of Sensei Biotherapeutics Inc (SNSE) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：9.17
Fair
-0.66
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Sensei Biotherapeutics Inc. (SNSE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.47. The thresholds are as follows: Strongly Undervalued below -8.26, Undervalued between -8.26 and -4.37, Fairly Valued between 3.42 and -4.37, Overvalued between 3.42 and 7.31, and Strongly Overvalued above 7.31. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.57
EV/EBIT
Sensei Biotherapeutics Inc. (SNSE) has a current EV/EBIT of 0.57. The 5-year average EV/EBIT is -0.44. The thresholds are as follows: Strongly Undervalued below -8.47, Undervalued between -8.47 and -4.45, Fairly Valued between 3.58 and -4.45, Overvalued between 3.58 and 7.59, and Strongly Overvalued above 7.59. The current Forward EV/EBIT of 0.57 falls within the Historic Trend Line -Fairly Valued range.
9.17
PS
Sensei Biotherapeutics Inc. (SNSE) has a current PS of 9.17. The 5-year average PS is 0.03. The thresholds are as follows: Strongly Undervalued below -1.11, Undervalued between -1.11 and -0.54, Fairly Valued between 0.61 and -0.54, Overvalued between 0.61 and 1.18, and Strongly Overvalued above 1.18. The current Forward PS of 9.17 falls within the Strongly Overvalued range.
0.00
P/OCF
Sensei Biotherapeutics Inc. (SNSE) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.43. The thresholds are as follows: Strongly Undervalued below -9.76, Undervalued between -9.76 and -6.09, Fairly Valued between 1.24 and -6.09, Overvalued between 1.24 and 4.91, and Strongly Overvalued above 4.91. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Sensei Biotherapeutics Inc. (SNSE) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.35. The thresholds are as follows: Strongly Undervalued below -10.23, Undervalued between -10.23 and -6.29, Fairly Valued between 1.59 and -6.29, Overvalued between 1.59 and 5.53, and Strongly Overvalued above 5.53. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Sensei Biotherapeutics Inc (SNSE) has a current Price-to-Book (P/B) ratio of 0.42. Compared to its 3-year average P/B ratio of 0.35 , the current P/B ratio is approximately 20.75% higher. Relative to its 5-year average P/B ratio of 0.59, the current P/B ratio is about -28.61% higher. Sensei Biotherapeutics Inc (SNSE) has a Forward Free Cash Flow (FCF) yield of approximately -209.93%. Compared to its 3-year average FCF yield of -165.28%, the current FCF yield is approximately 27.02% lower. Relative to its 5-year average FCF yield of -114.62% , the current FCF yield is about 83.15% lower.
0.42
P/B
Median3y
0.35
Median5y
0.59
-209.93
FCF Yield
Median3y
-165.28
Median5y
-114.62
Competitors Valuation Multiple
The average P/S ratio for SNSE's competitors is 3.08, providing a benchmark for relative valuation. Sensei Biotherapeutics Inc Corp (SNSE) exhibits a P/S ratio of 9.17, which is 197.76% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SNSE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SNSE in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Sensei Biotherapeutics Inc (SNSE) currently overvalued or undervalued?
Sensei Biotherapeutics Inc (SNSE) is now in the Fair zone, suggesting that its current forward PS ratio of 9.17 is considered Fairly compared with the five-year average of -2.64. The fair price of Sensei Biotherapeutics Inc (SNSE) is between to according to relative valuation methord.
What is Sensei Biotherapeutics Inc (SNSE) fair value?
How does SNSE's valuation metrics compare to the industry average?
What is the current P/B ratio for Sensei Biotherapeutics Inc (SNSE) as of Nov 04 2025?
What is the current FCF Yield for Sensei Biotherapeutics Inc (SNSE) as of Nov 04 2025?
What is the current Forward P/E ratio for Sensei Biotherapeutics Inc (SNSE) as of Nov 04 2025?